<DOC>
	<DOCNO>NCT02207816</DOCNO>
	<brief_summary>The purpose study conduct long-term surveillance efficacy , safety immunogenicity GSK Biologicals RTS , S/AS01E candidate Plasmodium falciparum malaria vaccine infant child Africa follow primary vaccination series ( NCT00866619 ) . No new subject enrol extension study .</brief_summary>
	<brief_title>An Extension Study MALARIA-055 PRI ( NCT00866619 ) Evaluate Long-term Efficacy , Safety Immunogenicity GSK Biologicals ' Candidate Malaria Vaccine Infants Children Africa</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) / Legally Acceptable Representative ( LARs ) , opinion investigator , comply requirement protocol . Subjects enrol receive least one vaccine dose primary study MALARIA055 PRI NCT00866619 withdraw consent ( except move away area ) primary study MALARIA055 PRI NCT00866619 . Written inform consent obtain parent ( ) /LAR ( ) subject . Child care . Use investigational nonregistered product plan use study period .</criteria>
	<gender>All</gender>
	<minimum_age>42 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Infants</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Children</keyword>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Safety</keyword>
	<keyword>Surveillance</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>RTS , S/AS01E</keyword>
	<keyword>Africa</keyword>
</DOC>